3BP has assembled a management team with broad experience in the pharmaceutical and biotechnology industries.
The team is led by co-founder Dr. Ulrich Reineke (Managing Director), who previously established and headed the biology research department at Jerini AG. He received his PhD from the Humboldt University Berlin and holds a Management Education degree from IMD Lausanne.
Dr. Christiane Smerling (Head of Nuclear Medicine & Imaging) is responsible for 3BP’s in-house research programs in nuclear medicine. Previously, she worked as a project leader at Jerini AG and received her PhD from the University of Cambridge (UK).
Dr. Jan Michel (Director of Finance and Corporate Development) previously worked as a management consultant at Capgemini and as a healthcare industry expert for Deutsche Bank. He is a certified international investment analyst (CIIA).
Dr. Ing. Thomas Polakowski (Head of R&D Cooperations and Strategic Technology Assessment) is leading 3BP’s research alliances. He previously led collaborative R&D projects at Jerini AG and held positions at Aventis Research and Technologies and Parexel International GmbH. Thomas received his PhD from the Technical University Berlin and holds an MBA (Project Management) from FOM University of Applied Sciences, Berlin.
Dr. Frank Osterkamp (Director Chemistry & Analytics) is heading medicinal chemistry at 3BP. He was responsible for several internal and collaborative peptide optimization programs at Jerini AG. He received his PhD from Humboldt University, Berlin.
Dr. Matthias Paschke (Director Biology & Assay Technologies) is heading the biology department. He previously developed and implemented several new screening and assay technologies and led collaborative projects at Jerini AG. Matthias received his PhD from the University Potsdam and led a research team at Charité - Universitätsmedizin Berlin.